A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)

Go Back to All Clinical Trials

A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)

Brief description of study

This is a two-stage, Phase 3, randomized, multi-center, controlled, open-label study comparing iberdomide maintenance to lenalidomide maintenance therapy after ASCT in participants with newly diagnosed multiple myeloma. The primary objective of this study is to compare the efficacy of iberdomide to that of lenalidomide maintenance after ASCT in participants with NDMM, as measured by PFS.

Clinical Study Identifier: s23-00361

ClinicalTrials.gov Identifier: NCT05827016

Principal Investigator: Gareth J. Morgan.

Other Investigators: Maxim Kreditor, Marc Justin Braunstein, Faith E. Davies, Yovanna Giovanis, Bruce G Raphael, Kenneth B Hymes, Oscar B Lahoud, John Leslie Vaughn, Ivy Mutibura, Shella Saint Fleur-Lominy, David Kaminetzky, Tibor Moskovits, Bonnie Kiner-Strachan, Thaleshravi Prashad.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies